Influenza control in the 21st century: Optimizing protection of older adults

Vaccine

Volumn 27, Issue 37, 2009, Pages 5043-5053

  Monto, Arnold S ^a   Ansaldi, Filippo ^b   Aspinall, Richard ^c   McElhaney, Janet E ^d,e   Montaño, Luis F ^f   Nichol, Kristin L ^g   Puig Barberà, Joan ^h   Schmitt, Joe ^i,j   Stephenson, Iain ^k  

^a UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF GENOA   (Italy)

^c CRANFIELD UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^g VA MEDICAL CENTER   (United States)

^h Public Health Research Centre   (Spain)

ⁱ JOHANNES GUTENBERG UNIVERSITY   (Germany)

^j GSK Marburg Vaccines and Diagnostics   (Germany)

^k LEICESTER ROYAL INFIRMARY   (United Kingdom)

more..

Author keywords

Influenza; Older adults; Protection

Indexed keywords

DNA VACCINE; INFLUENZA VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; VIROSOME VACCINE;

AGED; DIAGNOSTIC VALUE; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG MEGADOSE; ELDERLY CARE; GENETIC DRIFT; HUMAN; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; PRIORITY JOURNAL; REVIEW; STRAIN DIFFERENCE; T LYMPHOCYTE ACTIVATION; VIRUS STRAIN;

ADJUVANTS, IMMUNOLOGIC; AGED; ANTIGENS, VIRAL; COST OF ILLNESS; HEALTH POLICY; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; VACCINATION; VACCINES, ATTENUATED; VACCINES, VIROSOME;

EID: 67651026829     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.06.032     Document Type: Review

References (117)

1. Sprenger M.J.W., Mulder P.G.H., Beyer W.E.P., Van Strik R., and Masurel N. Impact of influenza on mortality in relation to age and underlying disease, 1967-1989. Int J Epidemiol 22 2 (1993) 334-340
2. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Cox N., Anderson L.J., et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289 2 (2003) 179-186
3. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Bridges C.B., Ox N.J., et al. Influenza-associated hospitalizations in the United States. JAMA 292 11 (2004) 1333-1340
4. McElhaney J.E. The unmet need in the elderly: designing new influenza vaccines for older adults. Vaccine 23 Suppl. 1 (2005) S10-25
5. Gavazzi G., and Krause K.H. Ageing and infection. Lancet Infect Dis 2 11 (2002) 659-666
6. World Health Organization (WHO). Influenza vaccines. Wkly Epidemiol Rec 80 33 (2005) 279-287
7. Centers for Disease Control and Prevention (CDC). Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR 57 (2008) 1-60
8. Palache A.M. Influenza vaccines. A reappraisal of their use. Drugs 54 6 (1997) 841-856
9. Nichol K.L. The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines. Vaccine 21 16 (2003) 1769-1775
10. Hannoun C., Megas F., and Piercy J. Immunogenicity and protective efficacy of influenza vaccination. Virus Res 103 1-2 (2004) 133-138
11. Legrand J., Vergu E., and Flahault A. Real-time monitoring of the influenza vaccine field effectiveness. Vaccine 24 44-46 (2006) 6605-6611
12. Carrat F., and Flahault A. Influenza vaccine: the challenge of antigenic drift. Vaccine 25 39-40 (2007) 6852-6862
13. World Health Organization (WHO). Fact sheet no. 211. March 2003. [Available at: http://www.who.int/mediacentre/factsheets/fs211/en. Accessed November 18, 2008].
14. Betts R.F., and Douglas R.G. Influenza virus. In: Mandell G.L., Douglas R.G., and Bennett J.E. (Eds). Principles and practice of infectious diseases (1990), Churchill Livingstone Inc., New York 1306-1325
15. Treanor J.J. Influenza vaccine-outmaneuvering antigenic shift and drift. N Engl J Med 350 3 (2004) 218-220
16. Hak E., Wei F., Nordin J., Mullooly J., Poblete S., and Nichol K.L. Development and validation of a clinical prediction rule for hospitalization due to pneumonia or influenza or death during influenza epidemics among community-dwelling elderly persons. J Infect Dis 189 3 (2004) 450-458
17. Qureshi A.M., Hughes N.J., Murphy E., and Primrose W.R. Factors influencing uptake of influenza vaccination among hospital-based health care workers. Occup Med (Lond) 54 3 (2004) 197-201
18. Yoshikawa T.T. Epidemiology and unique aspects of aging and infectious diseases. Clin Infect Dis 30 6 (2000) 931-933
19. Nguyen-Van-Tam J.S., and Nicholson K.G. Influenza deaths in Leicestershire during the 1989-1990 epidemic: implications for prevention. Epidemiol Infect 108 3 (1992) 537-545
20. Molinari N.A., Ortega-Sanchez I.R., Messonnier M.L., Thompson W.W., Wortley P.M., Weintraub E., et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 25 27 (2007) 5086-5096
21. Hospital Episode Statistics. Primary diagnosis: summary 2005-2006. [Available at: http://www.hesonline.nhs.uk/Ease/servlet/ContentServer?siteID=1937&c ategoryID=202. Accessed November 18, 2007].
22. Turner D.A., Wailoo A.J., Cooper N.J., Sutton A.J., Abrams K.R., and Nicholson K.G. The cost-effectiveness of influenza vaccination of healthy adults 50-64 years of age. Vaccine 24 7 (2006) 1035-1043
23. Fleming D., Harcourt S., and Smith G. Influenza and adult hospital admissions for respiratory conditions in England 1989-2001. Commun Dis Public Health 6 3 (2003) 231-237
24. Whitley R.J., and Monto A.S. Prevention and treatment of influenza in high-risk groups: children, pregnant women, immunocompromised hosts and nursing home residents. J Infect Dis 194 Suppl. 2 (2006) S133-138
25. Barker W.H., Borisute H., and Cox C. A study of the impact of influenza on the functional status of frail older people. Arch Intern Med 158 6 (1998) 645-650
26. High K.P., Bradley S., Loeb M., Palmer R., Quagliarello V., and Yoshikawa T. A new paradigm for clinical investigation of infectious syndromes in older adults: assessment of functional status as a risk factor and outcome measure. Clin Infect Dis 40 1 (2005) 114-122
27. Ferrucci L., Guralnik J.M., Pahor M., Corti M.C., and Haulik R.J. Hospital diagnoses, Medicare charges, and nursing home admissions in the year when older people become severely disabled. JAMA 277 9 (1997) 728-734
28. Falsey A.R., Hennessey P.A., Formica M.A., Cox C., and Walsh E.E. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 352 17 (2005) 1749-1759
29. Elixhauser A, Yu K, Steiner C, Bierman AS. Hospitalization in the United States, 1997. Rockville (MD): Agency for healthcare research and quality; 2000. HCUP Fact Book No. 1; AHRQ. Publication No. 00-0031. ISBN 1-58763-005-2.
30. Covinsky K.E., Palmer R.M., Fortinsky R.H., Counsell S.R., Stewart A.L., Kresevic D., et al. Loss of independence in activities of daily living in older adults hospitalized with medical illnesses: increased vulnerability with age. J Am Geriatr Soc 51 4 (2003 Apr) 451-458
31. Madjid M., Miller C.C., Zarubaev V.V., Marinich I.G., Kiselev O.I., Lobzin Y.V., et al. Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy-confirmed coronary heart disease death: results from 8 years of autopsies in 34,892 subjects. Eur Heart J 28 10 (2007) 1205-1210
32. Nichol K.L., Nordin J., Mullooly J., Lask R., Fillbrandt K., and Iwane M. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med 348 14 (2003) 1322-1332
33. Reichert T., Simonsen L., Shama A., Pardo S.A., Fedson D.S., and Miller M.A. Influenza and the winter increase in mortality in the United States, 1959-1999. Am J Epidemiol 160 5 (2004) 492-502
34. Fleming D.M., Cross K.W., and Pannell R.S. Influenza and its relationship to circulatory disorders. Epidemiol Infect 133 2 (2005) 255-262
35. Centers for Disease Control and Prevention (CDC). Influenza. In: Atkinson W., Hamborsky J., McIntyre L., and Wolfe S. (Eds). Epidemiology and prevention of vaccine-preventable diseases. 10th ed. (2008), Public Health Foundation, Washington DC 235-256
36. Fedson D.S. Preparing for pandemic vaccination: an international policy agenda for vaccine development. J Public Health Policy 26 1 (2005) 4-29
37. Van Essen G.A., Palache A.M., Forleo E., and Fedson D.S. Influenza vaccination in 2000: recommendations and vaccine use in 50 developed and rapidly developing countries. Vaccine 21 16 (2003) 1780-1785
38. Centers for Disease Control and Prevention (CDC). Role of laboratory diagnosis of influenza. [Last updated 2006. Available at: http://www.cdc.gov/flu/professionals/diagnosis/labrole.htm. Accessed November 18, 2008].
39. Jackson L.A., Jackson M.L., Nelson J.C., Neuzil K.M., and Weiss N.S. Evidence of bias in estimates of influenza vaccine effectiveness in seniors. Int J Epidemiol 35 2 (2006) 337-344
40. Simonsen L., Taylor R.J., Viboud C., Miller M.A., and Jackson L.A. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect Dis 7 10 (2007) 658-666
41. Vu T., Farish S., Jenkins M., and Kelly H. A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine 20 13-14 (2002) 1831-1836
42. Jefferson T., Rivetti D., Rivetti A., Rudin M., Di Pietrantonj C., and Demicheli V. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet 366 9492 (2005) 1165-1174
43. Hak E., Wei F., Nordin J., Mullooly J., Poblete S., Strikas R., et al. Influence of high-risk medical conditions on the effectiveness of influenza vaccination among elderly members of 3 large managed-care organizations. Clin Infect Dis 35 4 (2002) 370-377
44. Scuffham P.A., and West P.A. Economic evaluation of strategies for the control and management of influenza in Europe. Vaccine 20 19-20 (2002) 2562-2578
45. Maciosek M.V., Solberg L.I., Coffield A.B., Edwards N.M., and Goodman M.J. Influenza vaccination health impact and cost effectiveness among adults aged 50 to 64 and 65 and older. Am J Prev Med 31 1 (2006) 72-79
46. Patel M.S., and Davis M.M. Could a federal program to promote influenza vaccination among elders be cost-effective?. Prev Med 42 3 (2006) 240-246
47. Saurwein-Teissl M., Lung T.L., Marx F., Gschösser C., Asch E., Blasko I., et al. Lack of antibody production following immunization in old age: association with CD8(+)CD28(-) T cell clonal expansions and an imbalance in the production of Th1 and Th2 cytokines. J Immunol 168 11 (2002) 5893-5899
48. Lazuardi L., Jenewein B., Wolf A.M., Pfister G., Tzankov, and Grubeck-Loebenstein B. Age-related loss of naïve T cells and dysregulation of T-cell/B-cell interactions in human lymph nodes. Immunology 114 1 (2005) 37-43
49. Ahluwalia N. Aging, nutrition and immune function. J Nutr Health Aging 8 1 (2004) 2-6
50. Grubeck-Loebenstein B., Berger P., Saurwein-Teissl M., Zisterer K., and Wick G. No immunity for the elderly. Nat Med 4 8 (1998) 870
51. Miller J.F., and Davies J.S. Embryological development of the immune mechanism. Annu Rev Med 15 (1964) 23-36
52. Aspinall R., Del Giudice G., Effros R.B., Grubeck-Loebenstein B., and Sambhara S. Challenges for vaccination in the elderly. Immun and Ageing 4 December 11 (2007) 9
53. Ritter M.A., and Palmer D.B. The human thymic microenvironment: new approaches to functional analysis. Semin Immunol 11 1 (1999) 13-21
54. George A.J., and Ritter M.A. Thymic involution with ageing: obsolescence or good housekeeping?. Immunol Today 17 6 (1996) 267-272
55. Douek D.C., McFarland R.D., Keiser P.H., Gage E.A., Massey J.M., Haynes B.F., et al. Changes in thymic function with age and during the treatment of HIV infection. Nature 396 6712 (1998) 690-695
56. Andrew D., and Aspinall R. Il-7 and not stem cell factor reverses both the increase in apoptosis and the decline in thymopoiesis seen in aged mice. J Immunol 166 3 (2001) 1524-1530
57. Pido-Lopez J., Imami N., Andrew D., and Aspinall R. Molecular quantitation of thymic output in mice and the effect of IL-7. Eur J Immunol 32 10 (2002) 2827-2836
58. Henson S.M., Snelgrove R., Hussell T., Wells D.J., and Aspinall R. An IL-7 fusion protein that shows increased thymopoietic ability. J Immunol 175 September 15 (6) (2005) 4112-4118
59. Aspinall R., Pido-Lopez J., Imami N., Henson S.M., Ngom P.T., Morre M., et al. Old rhesus macaques treated with interleukin-7 show increased TREC levels and respond well to influenza vaccination. Rejuvenation Res 10 1 (2007) 5-17
60. World Health Organization (WHO). Recommendations for influenza vaccine composition. [Available at: http://www.who.int/csr/disease/influenza/vaccinerecommendations1/en/inde x.html. Accessed November 18, 2008].
61. Air G.M., Gibbs A.J., Laver W.G., and Webster R.G. Evolutionary changes in influenza B are not primarily governed by antibody selection. Proc Natl Acad Sci USA 87 10 (1990) 3884-3888
62. Cox N.J., and Bender C.A. The molecular epidemiology of influenza viruses. Sem Virol 6 6 (1995) 359-370
63. McCullers J.A., Wang G.C., He S., Webster R.G., and Reassortment. insertion-deletion are strategies for the evolution of influenza B viruses in nature. J Virol 73 September (9) (1999) 7343-7348
64. Yamashita M., Krystal M., Fitch W.M., and Palese P. Influenza B virus evolution: co-circulating lineages and comparison of evolutionary pattern with those of influenza A and C viruses. Virology 163 1 (1988) 112-122
65. Nerome R., Hiromoto Y., Sugita S., Tanabe N., Ishida M., Matsumoto M., et al. Evolutionary characteristics of influenza B virus since its first isolation in 1940: dynamic circulation of deletion and insertion mechanism. Arch Virol 143 8 (1998) 1569-1583
66. Shaw M.W., Xu X., Li Y., Normand S., Ueki R.T., Kunimoto G.Y., et al. Reappearance and global spread of variants of influenza B/Victoria/2/87 lineage viruses in the 2000-2001 and 2001-2002 seasons. Virology 303 1 (2002) 1-8
67. Smith D.J., Lapedes A.S., de Jong J.C., Bestebroer T.M., Rimmelzwaan G.F., Osterhaus A.D., et al. Mapping the antigenic and genetic evolution of influenza virus. Science 305 5682 (2004) 371-376
68. Ansaldi F., Bacilieri S., Durando P., Sticchi L., Valle L., Montomoli E., et al. Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and hemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses. Vaccine 26 12 (2008) 1525-1529
69. de Jong J.C., Beyer W.E., Palache A.M., Rimmelzwaan G.F., and Osterhaus A.D. Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J Med Virol 61 1 (2000) 94-99
70. Del Giudice G., Hilbert A.K., Bugarini R., et al. An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine. Vaccine 24 16 (2006) 3063-3065
71. Kojimahara N., Maeda A., Kase T., and Yamaguchi N. Cross-reactivity of influenza A (H3N2) hemagglutination-inhibition antibodies induced by an inactivated influenza vaccine. Vaccine 24 33-34 (2006) 5966-5969
72. Nordin J., Mullooly J., Poblete S., Strikas R., Petrucci R., Wei F., et al. Influenza vaccine effectiveness in preventing hospitalizations and deaths in persons 65 years or older in Minnesota, New York, and Oregon: data from 3 health plans. J Infect Dis 184 6 (2001) 665-670
73. Hagan D.T. New generation vaccine adjuvants. Encyclopedia of life sciences (2007), John Wiley and Sons, Ltd., Chichester, UK. http://www.mrw.interscience.wiley.com/emrw/047001590X/home [Available at: http://www.mrw.interscience.wiley.com/emrw/047001590X/home. Accessed November 9, 2008. Subscription required].
74. Podda A., and Del Giudice G. MF59 adjuvant emulsion. In: Levine M.M., Kaper J.B., Rappouli R., Liu M.A., and Good M.F. (Eds). New generation vaccines. 3rd ed. (2004), Marcel Dekker, Inc., New York 225-235
75. O'Hagan D.T. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infections. Expert Rev Vaccines 6 5 (2007) 699-710
76. De Donato S., Granoff D., Minutello M., Lecchi G., Faccini M., Agnello M., et al. Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. Vaccine 17 23-24 (1999) 3094-3101
77. Baldo V., Menegon T., Bonello C., Floreani A., Trivello R., and Collaborative Group. Comparison of three different influenza vaccines in institutionalised elderly. Vaccine 19 25-26 (2001) 3472-3475
78. Squarcione S., Sgricia S., Biasio L.R., and Perinetti E. Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects. Vaccine 21 11-12 (2003) 1268-1274
79. Li R., Fang H., Li Y., Liu Y., Pellegrini M., and Podda A. Safety and immunogenicity of an MF59™adjuvanted influenza subunit vaccine in elderly Chinese subjects. Immun Ageing 5 (2008) 2
80. Puig-Barberà J., and González Vidal D. MF59-adjuvanted subunit influenza vaccine: an improved interpandemic influenza vaccine for vulnerable populations. Expert Rev Vaccines 6 5 (2007) 659-665
81. Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 19 17-19 (2001) 2673-2680
82. Banzhoff A., Nacci P., and Podda A. A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis. Gerontology 49 3 (2003) 177-184
83. Baldo V., Baldovin T., Floreani A., Minuzzo M., and Trivello R. Response to influenza vaccine in people with non-protective HI antibody titers. Eur J Epidemiol 21 11 (2006) 843-845
84. Minutello M., Senatore F., Cecchinelli G., Bianchi M., Andreani T., Podda A., et al. Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. Vaccine 17 2 (1999) 99-104
85. Iob A., Brianti G., Zamparo E., and Gallo T. Evidence of increased clinical protection of an MF59-adjuvant influenza vaccine compared to a non-adjuvant vaccine among elderly residents of long-term care facilities in Italy. Epidemiol Infect 133 4 (2005) 687-693
86. Puig-Barberà J., Díez-Domingo J., Pérez Hoyos S., Belenguer Varea A., and González Vidal D. Effectiveness of the MF59-adjuvanted influenza vaccine in preventing emergency admissions for pneumonia in the elderly over 64 years of age. Vaccine 23 3 (2004) 283-289
87. Puig-Barberà J., Díez-Domingo J., Varea A.B., Chavarri G.S., Rodrigo J.A., Hoyos S.P., et al. Effectiveness of the MF59™-adjuvanted subunit influenza vaccine in preventing hospitalizations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly. Vaccine 25 42 (2007) 7313-7321
88. Leroux-Roels I, Clement F, Leroux-Roels G, Dramé M, Moris P, Devaster JM, et al. Adjuvanted influenza vaccines improve anti-influenza cellular mediated immunity impaired in elderly. Poster presented at: Influenza Vaccines for the World, October 18-20, 2006; Vienna, Austria.
89. Leroux-Roels I, Oostvogels L, Hons E, Leroux-Roels G, Devaster J-M, Ripley Ballou W. Reactogenicity and safety of adjuvanted influenza vaccines administered in elderly. Poster presented at: Influenza Vaccines for the World, October 18-20, 2006; Vienna, Austria.
90. Baras B, Jacob V, Méhauden S, Hanon E, Wettendorff M. Cross-protection in ferrets after vaccination with adjuvanted influenza split vaccine. Poster presented at: Influenza Vaccines for the World, 18-20 October, 2006; Vienna, Austria.
91. Treanor J.J., Mattison H.R., Dumyati G., Yinnon A., Erb S., O'Brien D., et al. Protective efficacy of combined live intranasal and inactivated influenza A virus vaccines in the elderly. Ann Intern Med 117 8 (1992) 625-633
92. Stepanova L., Naykhin A., Kolmskog C., Jonson G., Barantceva I., Bichurina M., et al. The humoral response to live and inactivated influenza vaccines administered alone and in combination to young adults and elderly. J Clin Virol 24 3 (2002) 193-201
93. de Bruijn I.A., Nauta J., Cramer W.C., Gerez L., and Palache A.M. Clinical experience with inactivated, virosomal influenza vaccine. Vaccine 23 Suppl. 1 (2005) S39-S49
94. Huckriede A., Bungener L., Stegmann T., Daemen T., Medema J., Palache A.M., et al. The virosome concept for influenza vaccines. Vaccine 23 Suppl. 1 (2005) S26-S38
95. ®) in elderly subjects. Vaccine 24 44-46 (2006) 6629-6631
96. Pregliasco F., Mensi C., Serpilli W., Speccher L., Masella P., and Belloni A. Immunogenicity and safety of three commercial influenza vaccines in institutionalized elderly. Aging (Milano) 13 1 (2001) 38-43
97. Keitel W.A., Atmar R.L., Cate T.R., Petersen N.J., Greenberg S.B., Ruben F., et al. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med 166 10 (2006) 1121-1127
98. Couch R.B., Winokur P., Brady R., Belshe R., Chen W.H., Cate T.R., et al. Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. Vaccine 25 44 (2007) 7656-7663
99. Frech S.A., Kenney R.T., Spyr C.A., Lazar H., Viret J.F., Herzog C., et al. Improved immune responses to influenza vaccination in the elderly using an immunostimulant patch. Vaccine 23 7 (2005) 946-950
100. Belshe R.B., Edwards K.M., Vesikari T., Black S.V., Walker R.E., Hultquist M., et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 356 7 (2007) 685-696
101. Ohmit S.E., Victor J.C., Rotthoff J.R., Teich E.R., Truscon R.K., Baum L.L., et al. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med 355 24 (2006) 2513-2522
102. Betts R.F., and Treanor J.J. Approaches to improved influenza vaccination. Vaccine 18 16 (2000) 1690-1695
103. Gorse G.J., O'Connor T.Z., Young S.L., Mendelman P.M., Bradley S.F., Nichol K.L., et al. Efficacy trial of live, cold-adapted and inactivated influenza virus vaccines in older adults with chronic obstructive pulmonary disease: a VA cooperative study. Vaccine 21 17-18 (2003) 2133-2144
104. Drape R.J., Macklin M.D., Barr L.J., Jones S., Haynes J.R., and Dean H.J. Epidermal DNA vaccine for influenza is immunogenic in humans. Vaccine 24 21 (2006) 4475-4481
105. Treanor J.J., Schiff D.M., Couch R.B., Cate T.R., Brady R.C., Hay C.M., et al. Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza virus hemagglutinin vaccine in elderly adults. J Infect Dis 193 9 (2006) 1223-1228
106. Frolov I., Hoffman T.A., Prágai B.M., Dryga S.A., Huang H.V., Schlesinger S., et al. Alphavirus-based expression vectors: strategies and applications. Proc Natl Acad Sci U S A 93 21 (1996) 11371-11377
107. Auewarakul P., Kositanont U., Sornsathapornkul P., Tothong P., Kanyok R., and Thongcharoen P. Antibody responses after dose-sparing intradermal influenza vaccination. Vaccine 25 4 (2007) 659-663
108. Kenney R.T., Frech S.A., Muenz L.R., Villar C.P., and Glenn G.M. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 351 22 (2004) 2295-2301
109. Chiu S.S., Peiris J.S., Chan K.H., Wong W.H., and Lau Y.L. Immunogenicity and safety of intradermal influenza immunization at a reduced dose in healthy children. Pediatrics 119 6 (2007) 1076-1082
110. Belshe R.B., Newman F.K., Cannon J., Duane C., Treanor J., Van Hoecke C., et al. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 351 22 (2004) 2286-2294
111. Holland D., Booy R., De Looze F., Eizenberg P., McDonald J., Karrasch J., et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J Infect Dis 198 5 (2008) 650-658
112. Gerhard W., Mozdzanowska K., and Zharikova D. Prospects for universal influenza virus vaccine. Emerg Infect Dis 12 4 (2006) 569-574
113. Beutner K.R., Chow T., Rubi E., Strussenberg J., Clement J., and Ogra P.L. Evaluation of a neuraminidase-specific influenza A virus vaccine in children: antibody responses and effects on two successive outbreaks of natural infection. J Infect Dis 140 6 (1979) 844-850
114. Bianchi E., Liang X., Ingallinella P., Finotto M., Chastain M.A., Fan J., et al. Universal influenza B vaccine based on the maturational cleavage site of the hemagglutinin precursor. J Virol 79 12 (2005) 7380-7388
115. Livingston B.D., Higgins D., and Van Nest G. Evolving strategies for the prevention of influenza infection: potential for multistrain targeting. BioDrugs 20 6 (2006) 335-340
116. Murasko D.M., Bernstein E.D., Gardner E.M., Gross P., Munk G., Dran S., et al. Role of humoral and cell-mediated immunity in protection from influenza disease after immunization of healthy elderly. Exp Gerontol 37 2-3 (2002) 427-439
117. McElhaney J.E., Xie D., Hager W.D., Barry M.B., Wang Y., Kleppinger A., et al. T cell responses are better correlates of vaccine protection in the elderly. J Immunol 176 10 (2006) 6333-6339